ライフサイエンスコーパス: vascular disorder

1 ry Hemorrhagic Telangectasia, a rare genetic vascular disorder.

2 elangiectasia type 2 (HHT2), a multisystemic vascular disorder.

3 logical candidate for predisposition to this vascular disorder.

4 nteric artery aneurysm (SMAA) is an uncommon vascular disorder.

5 such as neurofibromas and may associate with vascular disorder.

6 utic targets for the treatment of angiogenic vascular disorders.

7 ampering the development of gene therapy for vascular disorders.

8 n understanding the molecular basis of these vascular disorders.

9 an important insight into the mechanisms of vascular disorders.

10 steoporosis suggests a link between bone and vascular disorders.

11 othelial dysfunction, which is a hallmark of vascular disorders.

12 t of both normal immune response and various vascular disorders.

13 nt of many life-threatening and debilitating vascular disorders.

14 nd has been linked to various autoimmune and vascular disorders.

15 , little is known about division fidelity in vascular disorders.

16 tify S1PR2 as a novel therapeutic target for vascular disorders.

17 e metabolism that alleviate stroke and other vascular disorders.

18 ified several signaling pathways relevant to vascular disorders.

19 nephritis, chronic lung disease, sepsis, and vascular disorders.

20 hyperplasia and possibly other hyperplastic vascular disorders.

21 r age-related macular degeneration and other vascular disorders.

22 ow for potential new therapeutic targets for vascular disorders.

23 mmatory marker, are associated with systemic vascular disorders.

24 rdiovascular diseases, including obstructive vascular disorders.

25 ense mechanisms, atherosclerosis and related vascular disorders.

26 nse mechanisms, atherosclerosis, and related vascular disorders.

27 luding mental retardation and retinitis, and vascular disorders.

28 wth of VSMC and may thus contribute to human vascular disorders.

29 ading to their increasing use for thrombotic vascular disorders.

30 both rare single-gene and common multigenic vascular disorders.

31 role in the pathogenesis of inflammatory and vascular disorders.

32 VSMC) and has been implicated in a number of vascular disorders.

33 jury plays a key role in the pathogenesis of vascular disorders.

34 -A3 group and 19 [3%] in the placebo group), vascular disorders (30 [2%] vs 17 [3%]), and neoplasm (b

35 (41%), cardiac arrhythmias (40%), peripheral vascular disorders (39%), alcohol abuse (36%), valvular

36 e pathogenesis of atherothrombosis and other vascular disorders accompanied by endothelial dysfunctio

37 ional vascular biology and toward a range of vascular disorders and approaches in tissue regeneration

38 S) enzyme are characterized by a plethora of vascular disorders and hyperhomocysteinemia.

39 rdiovascular diseases, including obstructive vascular disorders and hypertension.

40 romboinflammatory activities in a variety of vascular disorders and vasculopathies.

41 deoxyribonucleotide with activity in several vascular disorders and, unlike t-PA and heparin, produce

42 angiectasia 2 (HHT2), a dominantly inherited vascular disorder, and pulmonary hypertension.

43 coagulation, systemic hypotension, ischemic vascular disorders, and autoimmune diseases.

44 tion, pigment epithelial detachment, retinal vascular disorders, and choroidal diseases and tumors.

45 an important contributing factor in multiple vascular disorders, and vascular lesion severity is temp

46 ontrast, the data supporting AD as a primary vascular disorder are more convincing.

47 However, the pathogeneses of the more common vascular disorders are not well characterized.

48 The long-term consequences of ART-associated vascular disorders are unknown and difficult to investig

49 ly debilitating and life-threatening genetic vascular disorder arising from endothelial cell (EC) pro

50 topia, a disorder that leads to epilepsy and vascular disorders, as well as embryonic lethality.

51 clusion (RVO) is a sight-threatening retinal vascular disorder associated with macular edema and neov

52 new approaches to the future therapeutics of vascular disorders associated with diabetes.

53 ologic relevance of O-GlcNAc modification in vascular disorders associated with diabetes.

54 resent a novel therapeutic strategy to treat vascular disorders by improving endothelial dysfunction

55 T) is a potentially life-threatening genetic vascular disorder caused by loss-of-function mutations i

56 rrier function and to the development of the vascular disorder Cerebral Cavernous Malformation (CCM).

57 onsible for the development of the inherited vascular disorder cerebral cavernous malformations (CCM1

58 elangiectasia (HHT) is an autosomal dominant vascular disorder characterized by epistaxis, mucocutane

59 editary hemorrhagic telangiectasia type 1, a vascular disorder characterized by multisystemic vascula

60 heterogeneous group of sporadic or inherited vascular disorders characterized by localized lesions of

61 Four deaths occurred on treatment due to vascular disorder (docetaxel plus capecitabine followed

62 Patients with known vascular disorders (eg, diabetes mellitus, coronary hear

63 mulin (Glmn), a protein found mutated in the vascular disorder glomuvenous malformation (GVM), binds

64 Two distinct pulmonary vascular disorders, hepatopulmonary syndrome (HPS) and p

65 mily type I receptor implicated in the human vascular disorder hereditary hemorrhagic telangiectasia

66 Retinal vein occlusion is a common retinal vascular disorder in the elderly population of Nepal.

67 ial clinical evidence for the development of vascular disorders in human immunodeficiency virus (HIV)

68 ivity of the smMLCK, perhaps contributing to vascular disorders in hypertension.

69 higher than expected prevalence of systemic vascular disorders in individuals with glaucoma has been

70 the presence of either organic or functional vascular disorders in these individuals.

71 s, W could also provide early information on vascular disorders in those clinical situations.

72 are established risk factors in a variety of vascular disorders including coronary artery disease and

73 ial function of this transcription factor in vascular disorders, including hypertension and atheroscl

74 c strategies in the treatment of a number of vascular disorders, including hypertension, atherosclero

75 d autoimmune diseases, as well as cancer and vascular disorders, including thrombosis.

76 ity are key events in the pathophysiology of vascular disorders induced by hypoxia.

77 nction and have fundamental implications for vascular disorders involving dysregulated eNOS.

78 This vascular disorder is responsible for 1-2% of all deaths

79 angiectasia (HHT), the most common inherited vascular disorder, is caused by mutations in genes invol

80 erlie the majority of inherited cases of the vascular disorder known as pulmonary arterial hypertensi

81 l hypertension (PAH) is a hyperproliferative vascular disorder observed predominantly in women.

82 epatopulmonary syndrome (HPS) is a pulmonary vascular disorder occurring as a consequence of advanced

83 Hypertension is a common multifactorial vascular disorder of largely unknown cause.

84 offers potential to improve visualization of vascular disorders of the eye.

85 Sympathetic nerves may play a role in vascular disorders of the eye.

86 viously included by the European Network for Vascular Disorders of the Liver, a multicenter prospecti

87 Arterioportal fistulas (APFs) are rare vascular disorders of the mesenteric circulation.

88 ranch vein occlusion (BVO), a common retinal vascular disorder, on protein tyrosine phosphorylation,

89 elp to identify therapeutic targets to treat vascular disorders or to promote or inhibit vessel growt

90 tastatic malignancies (OR = 2.1), peripheral vascular disorders (OR = 1.8), alcohol abuse (OR = 1.8),

91 nflammatory disorders, ocular tumor, retinal vascular disorders, other, normal, and unknown.

92 ura-has been identified as a risk factor for vascular disorders, particularly in women, but because o

93 cular or optic nerve head ischemic or ocular vascular disorders previously thought to be manifestatio

94 (BMPR-II) underlie the inherited form of the vascular disorder primary pulmonary hypertension (PPH).

95 er, other neurological disorders, peripheral vascular disorders, pulmonary circulation disorders, ren

96 on is associated with the pathophysiology of vascular disorders such as hypertension, atherosclerosis

97 n and is associated with a broad spectrum of vascular disorders such as impaired angiogenesis.

98 ls (hiPSCs) has great potential for treating vascular disorders such as ischemic retinopathies.

99 gen sulfide as a novel therapeutic agent for vascular disorders such as preeclampsia.

100 y in sEng release and its pathogenic role in vascular disorders such as preeclampsia.

101 Little is known about autophagy in other vascular disorders, such as aneurysm formation, arterial

102 m contributes to the pathogenesis of several vascular disorders, such as atherosclerosis, restenosis,

103 underlying angiogenesis, arteriogenesis, and vascular disorders, such as HHT and pulmonary hypertensi

104 cular or optic nerve head ischemic or ocular vascular disorders, the ophthalmologist should talk to t

105 ic molecule that prevents the development of vascular disorders when administered prophylactically.

106 monary hypertension, a progressive pulmonary vascular disorder with high morbidity and mortality.

107 utations in other genes for HHT and possibly vascular disorders with overlapping phenotypes.